ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
PU
Peking University Cancer Hospital at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Peking University Cancer Hospital takes part in 25 sessions at ESMO 2026 in Madrid. Its program spans melanoma and gastrointestinal cancers, with attention to targeted and immune-based treatments. It examines whether MRI can identify colon cancer patients who may preserve their organs after immunotherapy.
| Organization | ESMO 2026 Attendance |
|---|---|
PU Peking University Cancer Hospital Beijing, China | |
Cancer hospital and research institute of Peking University in Beijing, China. | Poster Fri Oct 23 13:00–15:00 Al18F-HER2-BCH PET/CT guided precision neoadjuvant therapy for HER2-positive early breast cancer: FHERNAT trial Breast cancerBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Dynamic Changes in Circulating Tumor Cells (CTCs), HER-2 Expression, and Aneuploidy Predict Treatment Response and Recurrence in Muscle-Invasive Bladder Cancer (MIBC) Receiving Neoadjuvant Disitamab Vedotin (DV) Plus Toripalimab: An Updated Analysis Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Neoadjuvant tislelizumab plus lenvatinib for resectable hepatocellular carcinoma and efficacy prediction by dynamic circulating tumor DNA monitoring: Preliminary results of a phase II study Gastrointestinal cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Prospective, single-arm, single-center phase II clinical study of perioperative precision treatment for locally advanced hepatoid adenocarcinoma of stomach (HASCHANGE01) Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 A first-in-human phase I study evaluating the safety, tolerability, and preliminary antitumor activity of CRPA1A2, a HLA-A*02:01-restricted MAGE-A1-targeting T cell engager, in patients with advanced solid tumors Gastrointestinal cancersSarcoma, CNS, head & neck and rare cancers Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Abstract Fri Oct 23 17:10–17:20 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Phase 1b/2 trial of BGB-A445 (OX40 agonist) with or without tislelizumab in urothelial carcinoma, renal cell carcinoma, and melanoma Melanoma & skin cancersGenitourinary cancers Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Transcriptomic and epigenomic profiling of TIL products identifies determinants of clinical benefit in autologous TIL therapy (LM103) for advanced melanoma Melanoma & skin cancersBiomarkers & precision oncology Abstract Sat Oct 24 15:47–15:57 Talk Sat Oct 24 19:15–19:30 Presentation of a clinical case: Improving patient tolerability of first line therapeutic options Gastrointestinal cancersBiomarkers & precision oncology Abstract Sun Oct 25 09:27–09:32 Abstract Sun Oct 25 09:32–09:42 Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Poster Sun Oct 25 12:00–12:45 Multi-omics landscape of metastatic gastric cancer microenvironment reveals Focal Adhesion Kinase signaling as a potential therapy against peritoneal metastasis Gastrointestinal cancersBiomarkers & precision oncology Poster Sun Oct 25 12:00–12:45 Chair Mon Oct 26 08:30–10:00 Advancing targeted and immunotherapeutic strategies in upper GI cancer Gastrointestinal cancers Talk Mon Oct 26 09:15–09:30 Personalised vaccines and cell therapies Gastrointestinal cancers Abstract Mon Oct 26 10:15–10:25 Abstract Mon Oct 26 10:25–10:35 Poster Mon Oct 26 12:00–12:45 Efficacy of systemic therapies across lines in EP-NEC: Meta-analysis with contextualization of opamtistomig (LBL-024) Sarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 Irinotecan liposome plus vincristine and apatinib for relapsed/refractory adult rhabdomyosarcoma: An exploratory study Sarcoma, CNS, head & neck and rare cancers Poster Mon Oct 26 12:00–12:45 |
Find decision makers at Peking University Cancer Hospital
Tell us what you sell and we’ll find the people at Peking University Cancer Hospital most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction